Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UPVPARDS
ChiCTR-IPD-17011387Phase 4Not yet recruiting
- Sponsor
- The Third Hospital of Hebei Medical University
- Start
- Aug 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of ulinastatin in sepsis and acute respiratory distress syndrome (ARDS) (3 arms), sponsored by The Third Hospital of Hebei Medical University. Primary endpoint: Clinical and prognostic indicators. Planned start Aug 2017; status: not yet recruiting.
02
Drugs
ulinastatin
03
Conditions
sepsisacute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on ChiCTR-IPD-17011387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPD-17011387.